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FDA’s Quality Systems Methodology  










This research details the FDA’s quality systems methodology used in its inspection of bio-
pharmaceutical manufacturers in the time period between 2003 and 2009. It analyzes the 
violations specified in FDA site inspection warning letters, reviewing their frequency and 
specificity. This analysis is an exploration into FDA activity in this sector, focusing particularly 
on finished pharmaceuticals, and serves as an initial evaluation of the FDA’s performance. In 
addition, the study pays particular attention to whether the FDA’s risk methodology has 
enhanced the overall inspection process and increased its quality assurance. 
 
 
U.S.A. FOOD AND DRUG ADMINISTRATION (FDA) 
 
This paper is the result of an ongoing examination of the FDA’s new risk methodology, as it is 
applied to the manufacturing sector of the bio-pharmaceutical (BP) industry. It specifically 
addresses the manufacturing facilities that produce finished pharmaceuticals, including drugs for 
humans. As a basis for this study, the researchers continue to review FDA regulations and 
procedural manuals that relate to inspections and quality systems (QS), as well as examining 
violation warning letters issued to BP facilities from 2003 to 2009. 
 
The FDA is continually seeking to improve its oversight of the BP industry, and in 2004 it 
announced that it would incorporate a risk-based methodology in its inspection of manufacturing 
processes. The data generated since this announcement up until 2009, provides sufficient 
information to analyze whether this decision has improved the FDA oversight process. To judge 
this new approach, the researchers evaluated the FDA data as to whether more inspections have 
been made, more violations found, and better guidance provided during this time period. The 
researchers gathered data from site inspections, grouped them into categories showing the 
number and type of annual manufacturing inspections, and then examined the type of violations 
and their frequency, as detailed in the warning letters (WLs) issued to manufacturers. 
 
This task of gathering and analyzing data from thousands of inspections that occur at diverse 
manufacturing facilities around the country is significant and complex. However, the Freedom of 
Information Act of 2008 (FDA, 2008d) has released much important data concerning site visits. 
This then becomes a database problem of collecting, sorting and extracting information from the 
multiple folders found at the FDA web site. Consequently, the researchers made the decision to 
focus on one particular subset within the BP industry—that of drugs and biological products. 
Choosing this FDA sector allows a comparison to be made between similar manufacturing sites, 
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while using the same FDA inspection methodology. Thus it becomes easier to understand how 
the FDA performs its quality assurance inspections, and how well the agency performs its 
oversight function (Alavi & Leidner, 2001). 
 
More specifically this paper reviews and analyzes how quality assurance systems and risk 
methodology (as detailed in FDA regulations Part 210 and Part 211 - Current Good 
Manufacturing Practice (cGMP) for Finished Pharmaceuticals) is incorporated within the FDA 
oversight rubric. Within Parts 210 and 211, the study focuses particularly on the concepts of 
corrective and preventative action (CAPA) to assure sustainable compliance. CAPA is a critical 
component in measuring risk, since problem prevention, containment, and remediation are 
intrinsic in determining the outcome (COSO, 2004). 
 
The FDA is a large, complex, and sophisticated agency, and therefore this research can be only 
an initial investigation into its CAPA activities in one sector. By reviewing the timeframe 2003-
2009, the research is establishing some baselines for performance, and for judging CAPA 
activities. This is an area that is not widely explored, other than by the Center for Drug 
Evaluation Research (CDER), a part of the United States Department of Health and Human 
Services, Food and Drug Administration (FDA) papers and congressional reports. Some 
additional information about QS and risk are usually found on pharmaceutical consulting sites. In 
the first instance, the information is a general overview and more informative than evaluative. In 
the latter instance, the information presented is often proprietary and seemingly aimed at 
generating client assignments. The two principal academic investigations of FDA and CAPA that 
we are aware of are Adis (2007, 2008) in his review of risk control systems, and Macher and 
Nickersons (2006) review of QS. 
 
 
FDA’S CURRENT GOOD MANUFACTURING PRACTICES METHODOLOGY 
 
The FDA’s principal objective is ensuring public safety through establishing industrial quality 
standards, guidance, and oversight. It functions as the responsible supervisory agency, mandating 
quality systems (GAMP, 2001) in all aspects of the manufacturing life cycle of drugs, vaccines, 
and other biological products. Its oversight tasks are to inspect facilities, examine biological 
products and manufacturing processes, issue warning letters, and take enforcement action, such 
as ordering recalls. The compliance guidelines (FDA, 2003a; FDA, 2004a) establish an 
exceptionally low tolerance for variability or deviation in all pharmaceutical products. 
 
The FDA uses a best practice methodology as its criteria for performance. It has now added to 
this a new risk-based paradigm for performing its inspections and accomplishing its oversight 
tasks (de Neufville, 2004). Before this date, the FDA’s own internal reviews made it clear that 
there were problems in meeting its objectives. It realized that its limited budget, lack of qualified 
staff and inadequate resources prevented it from meeting its goals of inspecting domestic BP 
facilities within a 2 year cycle, or a 4 year cycle for more complex products and processes. It also 
became clear that the number of BP research and production sites would continue to grow, while 
the FDA resources would remain relatively unchanged. This would create an increasing and 
untenable backlog, as the FDA failed to keep up with its site visits and inspections. To meet this 
oversight bottleneck, the FDA chose to supplement its industrial best practices with a quality 
FDA’s Quality Systems Methodology at Pharmaceutical Manufacturing Sites Adis 
 
Communications of the IIMA © 2011 29 2011 Volume 11 Issue 1 
assurance methodology that orders and prioritizes BP sites based on their associated risk (FDA, 
2004b). This transition began in 2004, when the agency adopted this new risk-based 
methodology, outlined in part by the Pharmaceutical Current Good Manufacturing Practices 
(cGMP) for the 21st Century (FDA, 2004a). 
 
This methodology guides the oversight process by choosing which manufacturing facilities have 
the highest risk priority, determining the focus for the site inspection, and whether warning 
letters and recalls are necessary (FDA, 2008b). “The model is based on a risk-ranking and 
filtering method that is well-recognized, objective, and rigorously systematic. This approach 
should help the Agency make the best use of its limited surveillance and enforcement resources, 
while maximizing the impact of those resources on the public health” (FDA, 2004a). 
 
Therefore, to the FDA’s normal inspection schedule there have been added priority site visits for 
those manufacturing facilities that have a previous history of warning letters, or perform 
processes that have an inherently higher risk of system failure. CAPA requirements are often 
integrated within the regulations, as the inspections emphasize systems to monitor performance, 
and correct and remediate anomalies (ICH, 2005). During the site visit, inspectors determine 
whether these monitoring and remediation systems are in place. Then during the course of the 
year, the FDA updates its quality assurance database, adding its findings about the frequency and 
severity of nonconforming production practices (FDA, 2008a). By applying this risk 
methodology, the FDA filters and prioritizes the data to focus on those that represent the greatest 
hazard. This is done by using the industries best business practices combined with risk 
management statistics. In this way, the FDA builds a performance history for each manufacturer 
and then schedules site visits and evaluations focusing on these key risk indicators (ICH, 2007):  
 Overall compliance status and history of the company or facility 
 Results of the company’s quality risk management activities 
 Complexity of the manufacturing process 
 Complexity of the product and its therapeutic significance 
 Number and significance of quality defects (e.g., recalls) 
 Results of previous audits/inspections 
 
 
QUALITY SYSTEMS CAPA AND HUMAN DRUGS 
 
This study focuses on inspections of facilities that produce human drugs, and asks how the FDA 
has incorporated regulations that achieve quality systems (QS) and CAPA outcomes. This is 
particularly important since QS and CAPA are critical components in FDA oversight and are the 
basis for an effective risk methodology. 
 
The category “human drugs” falls within the domain of the Center for Drug Evaluation Research 
(CDER). Its tasks are to “evaluate the findings of inspections that examine the conditions and 
practices in plants where drugs are manufactured, packed, tested and stored.… We identify, 
evaluate and analyze inspection findings for trends in deficiencies. We publish guidance to assist 
drug manufacturers and distributors in gaining a better understanding of our regulations.… We 
determine which manufacturers are acceptable to supply active pharmaceutical ingredients or 
finished drug products to the U.S. market.” (CDER, 2007). 
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The CDER monitors its functional areas using specific guidelines. For human drugs, it bases its 
enforcement on Part 210 - cGMP in Manufacturing, Processing, Packing, or Holding of Drugs, 
and Part 211 - cGMP for Finished Pharmaceuticals. 
 
Part 210 is a general series of regulations defining cGMP facilities/processes and human drug 
characteristics. The enforcement goals and inspection objectives are defined in Part 211. In those 
regulations it spells out staffing requirements, production controls, and necessary reports. It 
should be noted that Part 211 does not directly address quality systems or CAPA, as do other 
regulations, most notably 820.100 (Corrective and Preventive Action) within the FDA sector for 
manufacturing medical devices (Crosse, 2008). The researchers initially found this surprising, 
given the risk emphasis found in cGMP. Consequently, it became important to find out how 
CDER implements its Part 211 and whether it achieves the same effect as using CAPA 
methodology to assure oversight. 
 
This is how CDER’s addresses this issue: “Nonetheless, FDA recognizes that each set of 
regulations is somewhat different because each is tailored to the characteristics of the types of 
products for which they were designed…. Typically, these express/specific requirements are 
related to the unique characteristics of a drug, device, or biological product. For example:  
 Corrective and preventive action (CAPA): The QS regulation has detailed CAPA 
requirements (21 CFR 820.100), while CAPA principles are more generally identified in 
the CGMP regulation as part of Production Record Review (21 CFR 211.192).” (CDER, 
2010). 
 
As the CDER statement points out, CAPA requirements are spelled out in regulation 211.192, 
Production Record Review. Yet since this research is an initial review of CDER, the researchers 
made the decision to review all the regulations that made up Part 211, with a special focus on 
regulation 211.192. This was done to get an overview of the interplay between the regulations, 
and to see how other 211 regulations contribute to the tasks of CAPA data management and 
quality system analysis. The next section reviews the methodology for analyzing the how CDER 





The researchers examined the warning letters that specifically dealt with cGMP, quality 
assurance and CAPA. As mentioned in the previous section, the research looked into the WLs to 
determine to what degree CAPA was integrated into cGMP inspection methodology. Using the 
Freedom of Information Act, the research was able to reviews WLs that met the following 
criteria: 
 Issued in 2003-2009 time frame 
 Subject was cGMP found in regulations 501(h) of the Act (21 U.S.C. §351(h)) 
 Included FDA regulations Part 210 and Part 211, cGMP Practice for Finished 
Pharmaceuticals  
 QS and CAPA risk methodology as mentioned directly or indirectly in Part 211 
 
This can be visually captured in Figure 1, which illustrates the granular focus of the research. 
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Figure 1. Granular Analysis of Warning Letters. 
 
 
Total Inspections > WL > cGMP violations > Quality Assurance 211 > Subparts 
A–K > 
 Several important examples: 
Subpart B--Organization and Personnel  
Subpart F--Production and Process Controls  
Subpart I--Laboratory Controls  
Subpart J--Records and Reports  
 
Much of this information can be sourced from the FDA’s Field Activities – Office of Regulatory 
Affairs (FDA, 2008c) and other similar reports to Congress (CDER, 2011). These congressional 
reports provide useful data on budgets and staffing, as well as field activities. By collating data 
from these reports, it was straightforward to determine the total number of site inspections per 
year, as well as those that triggered WLs. Information derived from the CDER field manuals and 
inspection guidelines showed that generally there were two kinds of field visits. The first were 
regularly scheduled inspections, or in certain instances re-visits to ascertain that a previous 
violation had been satisfactorily resolved. The second type were risk based, determined by the 
pharmaceutical manufacturing processes used, the type of biological products produced, and the 
site violation history of the plant. Or in FDA language, site selection is based on using a model 
that provides a risk score for each facility, which is a function of four component risk factors – 
Product, Process, Facility, and Knowledge. 
 
The first step then becomes calculating the total number of cGMP Part 211 based site 
inspections. This information is found in Table 1, column A (CDER, 2011). Reviewing Table 1, 
several things become evident. There is no obvious improvement in CDER performance after the 
2004-2005 implementation of the new risk methodology. Rather the data suggests a general 
decrease in the number of inspections over the last five years (column A), falling from 1365 to 
983. This represents 382 fewer site inspections, or 28% over 5 years. This decrease of 28% is in 
keeping with FDA problems of limited staff, budget, and resources that prevent the agency from 
keeping up with the inspection of manufacturing sites. However, CDER estimates that in 2010 
and 2011 its goal will be in the range of 993 inspections, a modest improvement. 
 












2003 1,149 35 3.0% 
2004 1,232 26 2.1% 
2005 1,365 14 1.0% 
2006 1,222 20 1.6% 
2007 1,073 13 1.2% 
2008 972 29 3.0% 
2009 983 26 2.6% 
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The next column (B) focuses on inspections that resulted in WLs being issued for Part 211 
violations. During the time period 2003 to 2009, the WLs in this category ranged from 13 to 35. 
Neither the number of WLs nor their percentages seem particularly significant, given the large 
number of inspections. Column C highlights the lack of any particular impact from using cGMP 
risk methodology, with the WLs staying within 1% to 3% of the yearly inspections, regardless of 
methodology. 
 
Furthermore, the paucity of WLs put paid to the notion that the FDA is concentrating on the most 
risk prone manufacturers. At least so far, it could be argued that the cGMP new emphasis on risk 
has not increased the number of inspections performed by staff, nor caused more WLs to be 
issued. In fact one could argue that the opposite exists, with few inspections, and few sites with 
violations. 
 
The research then further analyzed the same cGMP WLs to see how many emphasized quality 
assurance and CAPA related regulations. This more granular analysis is important because it 
addresses whether the FDA is actually emphasizing the CAPA related regulations which are 
fundamental to risk analysis. This task was done by searching and categorizing the contents of 
each of the Part 211 WLs. Table 2 begins this process by showing the 211 Subparts cited in the 
WLs, and displaying the total count over the 5 year period (2005-2009) after the risk 
methodology formally became part of the inspection process. 
 
Subpart A provides a general statement of the role of the regulations, which are found on all 
WLs, and are therefore not applicable. The remaining Subparts (B-K) are displayed, with the 
count of the number of times the field inspectors cited them during this period (column A), as 
well as their yearly average (column B). Particularly noteworthy is Subpart J, Records and 
Reports, for its high 5 year count of 176 citations, and its average count of 35.2 per year. The 
176 citations represent 29% of all 604 citations for that five year period (column C). Furthermore 
when the researchers reviewed raw data for the last two years, they found that in 2008, Subpart J 
had 57 citations, while in 2009 it had 45. This finding points to the fact that Subpart J continues 
to be an increasingly important regulation. 
 
Table 2:  Part 211 Subparts A-K Citations within WLs (2005-2009). 
 







A. General Provisions N/A   
B. Organization and Personnel  60 12.0 10% 
C. Buildings and Facilities  34 6.8 6% 
D. Equipment  60 12.0 10% 
E. Control of Components and Drug Product 
Containers and Closures  39 7.8 6% 
F. Production and Process Controls  85 17.0 14% 
G. Packaging and Labeling Control  29 5.8 5% 
H. Holding and Distribution  5 1.0 1% 
I. Laboratory Controls  115 23.0 19% 
J. Records and Reports  176 35.2 29% 
K. Returned and Salvaged Drug Products  1 0.2 0% 
Total 5-Year Count of Citations 604   
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In summary, those Subparts (B, D, F, I, J) that address quality assurance are the most frequently 
cited regulations over the time period 2005-2009. They make up in total 82% percent of all 
recorded citations. This makes sense since the FDA seems to be looking for the BP staff and 
their systems to collect, record, and report quality assurance data on the site. 
 
Table 3 takes a more granular look at specific Subpart B-K regulations, reporting on those that 
were cited more frequently. In keeping with the overall paucity of WLs per year, only 
regulations that were cited a minimum of 5 times per year were displayed. As Table 3 shows, 
there were only 9 regulations out of the 58 (B-K) that met this criterion. All had QA and data 
reporting components which are necessary for quality systems and CAPA. As an example, take 
211.22 - Responsibilities of quality control unit. By emphasizing this regulation, CDER is 
fostering a well-managed quality environment. The remaining 8 regulations also focus on testing, 
logging, and procedures. 
 
One of the research themes was to understand on how CDER uses Subpart J 211.192, the 
enforcement of corrective and preventative activities. This is important since it is the cornerstone 
for building QS CAPA systems. This regulation is noteworthy with an average of 12 citations per 
year; with the yearly data showing that during the last 2 years there have been an increased 
number of citations. In 2008, for 211.192 there were 21 violations, and 2009 there were 16 
violations. Certainly an improvement, but given the overall low numbers not overwhelming. 
Similar to comments made earlier about the paucity of WLs, Table 3 has few citations. As a 
matter of fact of the 58 regulations from Subpart B-K, 33 were cited on average less than once 
over the last 5 years. This unexpected result leads to the assumption that the FDA only focuses 
on certain priority QS and CAPA activities, as listed in Table 3. These nine regulations are cited 
a total of 334 times over this five year period. This represents 55% of the 604 citations that were 
found in the Part 211 WLs. 
 
This is a targeted rather than a broad comprehensive approach. It may very well be that passing 
or failing is based principally on meeting the criteria posed by these nine regulations. Again, this 
is in keeping with the limited resources available to CDER. 
 










B 211.22 - Responsibilities of quality control unit. 48 9.6 
D 211.67 - Equipment cleaning and maintenance. 34 6.8 
F 211.100 - Written production procedures; deviations. 34 6.8 
F 211.113 - Control of microbiological contamination. 28 5.6 
I 211.160 - General lab requirements. 43 8.6 
I 211.165 - Lab testing and release for distribution. 31 6.2 
I 211.166 - Lab stability testing. 31 6.2 
J 211.188 - Batch production records. 25 5.0 
J 211.192 - Production record review. 60 12.0 
 Total 334  
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DISCUSSION 
 
This research, focusing on finished pharmaceuticals in the BP sector, is just one of many avenues 
that can shed more light on the FDA’s risk based approach. 
Other areas could include  
 the raw data found on the CDER site inspection form (FDA 483) used by the examiner  
 the manufacturer’s written responses to the WL 
 data specifically about product recalls, fines and penalties  
 
A broader research agenda may point to a different understanding of the FDA inspection process. 
Furthermore, a detailed comparison of the findings in the WLs with the FDA inspection manuals 
and quality assurance guidelines (FDA, 2003b; FDA, 2008e; FDA, 2008f) would add greater 
depth. In addition there is some evidence that WLs are vetted by the FDA’s legal staff to prevent 
lawsuits claiming a biased inspection process (Goldstein, 2008). Part of this possible FDA 
vetting as well as the sameness in style, format, expressions, and perhaps even content, may be 
the result of the EIR Turbo computer software that the FDA has used since 2002 to automate the 
process of writing inspection reports and WLs (Betterchem, 2008). 
 
While this research did not formally address the WL data from the manufacturers perspective, it 
did have the advantage of reviewing previous BP and FDA studies (Macher & Nickerson 2006; 
Adis, 2007, 2008). At this stage of the research there have been only preliminary discussions 
with the BP industry concerning quality assurance issues and their use of manufacturing 
execution systems software. Expanding the research to include manufacturers makes sense, and 
will be explored in future studies now that this work has established some baselines. 
 
These limitations were kept in mind during this study and will in part be addressed as this 
research continues to probe the issues of quality and risk found in the FDA methodologies. Yet it 
seems fair to say that these initial findings can serve as a benchmark for understanding how the 
FDA is responding in terms of policy and direction to their internal problem of limited resources 





However, in spite of these research limitations, findings drawn from this study provide some 
basic insights into the FDA CDER oversight activity. The findings also confirm the budgetary 
and resource problems faced by the FDA, and the inability of the risk methodology to 
significantly change the downward trend in inspections and WLs. The data clearly show that the 
FDA is doing less cGMP inspections in this sector over the last 5 years. While the WLs do focus 
on QS CAPA issues, most of the citations are of a general nature, using few of the regulations 
within each of the Subparts. 
 
In summary, the findings show  
 Fewer FDA inspections over the time period 2005-9 
 Correspondingly, few cGMP WLs were issued 
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 Even when WLs were issued, they were narrowly focused on a few Subparts (B, D, F, I, 
J) 
 While these Subparts dealt with QS CAPA, relatively few regulations were actually used  
 Overall, few 211 regulations were cited in the WLs  
 
These findings may be the result of manufacturers adopting manufacturing execution systems 
software (MES), such as SAP R/3 and Trackwise. The increased use of these automation and 
monitoring systems contribute to dramatic improvements in BP manufacturing, and meet many 
of the reporting requirements mandated by CDER regulations. Table 4 displays some of SAP’s 
MES software used in BP manufacturing for the monitoring, control and reporting of the 
manufacturing process. SAP software was chosen as it is the largest supplier of software to the 
BP industry. 
 
Table 4: SAP R/3 Software for the BP Industry. 
 
SAP Enterprise Sub Systems 
Supply Chain Management System (SCMS)  
Supplier Relationship Management (SRM)  
Customer Relationship Management (CRM)  
Materials Management (MM)  
Quality Management (QM) 
Corrective and Preventive Actions (QM-CAPA) 
 Laboratory Information Management System (LIMS) 
 Advanced Planner and Optimizer (APO) 
 Plant Maintenance (PM) 
Environmental Health & Product Safety (EH&S)  
 
The FDA may very well be using the inspection process as a policy tool to move the 
manufacturers to the need for MES quality systems. If so, there is some logic to the paucity of 
WLS and the less detailed approach to the oversight process. Through the adoption of MES, 
manufacturers would be more likely to obtain a ‘necessary and sufficient’ standard for passing 
inspections. They would meet both best practices as well as the reporting component necessary 
for the risk methodology. This premise will be tested in further research. However, if one of the 
purposes of the FDA inspections is direct QS CAPA oversight, then MES software alone will be 
insufficient. 
 
By failing to detail the specific inspection violations, the FDA is not providing the necessary 
guidance to the industry. The QS CAPA risk methodology within the 211 quality assurance 
framework has the potential to both provide guidance and detail weaknesses within the 
manufacturers’ production processes. With detailed WL information, manufacturers can be better 
guided in implementing superior QS CAPA systems to correct and prevent system failures. Even 
with those that have adopted MES software, the inspections can still address the production 
issues of staffing and training, monitoring frequency, batch controls and reporting. Certainly that 
is a realistic expectation for the FDA. 
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